Retrospective Study
Copyright ©The Author(s) 2024.
World J Diabetes. Sep 15, 2024; 15(9): 1903-1915
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1903
Table 5 Results of stratified analysis between age and subfoveal choroidal thickness in patients with proliferative diabetic retinopathy
Y = SFCT, μm
n
β, 95%CI
P value
Gender
    Female99-0.38 (-2.39 to 1.64)0.7157
    Male135-2.63 (-4.51 to -0.74)0.0074
Hypertension history
    No126-1.19 (-2.65 to 0.27)0.1137
    Yes108-3.27 (-5.42 to -1.12)0.0037
Education level
    Junior high school or below147-2.13 (-3.90 to -0.36)0.0198
    Senior high school40-0.72 (-4.44 to 3.00)0.7086
    College or above44-2.09 (-5.23 to 1.06)0.2054
Diabetic nephropathy history
    No188-1.76 (-3.06 to -0.46)0.0089
    Yes46-1.29 (-6.51 to 3.94)0.6341
Stroke history
    No222-1.48 (-2.80 to -0.16)0.0294
    Yes12Not applicable
Heart disease history
    No222-1.61 (-2.90 to -0.32)0.0153
    Yes12Not applicable
Anemia history
    No162-2.62 (-4.15 to -1.08)0.0011
    Yes721.16 (-1.62 to 3.93)0.4176
PRP
    None1110.05 (-1.78 to 1.87)0.9602
    Partial43-3.64 (-6.62 to -0.66)0.0257
    Whole80-4.56 (-7.00 to -2.11)0.0006
Anti-VEGF therapy
    No175-1.03 (-2.56 to 0.50)0.1891
    Yes59-3.95 (-6.57 to -1.32)0.0055
Insulin treatment
    No113-1.16 (-2.82 to 0.49)0.1711
    Yes121-2.34 (-4.42 to -0.25)0.0304
Oral glucose-lowering drugs
    No59-2.85 (-5.15 to -0.56)0.0180
    Yes175-2.13 (-3.27 to -0.99)0.0003
Calcium antagonists
    No183-1.27 (-2.56 to 0.02)0.0550
    Yes50-3.00 (-7.47 to 1.48)0.1993
Total cholesterol group (mmol/L)
    < 6.22119-1.78 (-3.74 to 0.18)0.0788
    ≥ 6.2212Not applicable
eGFR group (mL/minutes × 1.73 m2)
    < 3030-3.83 (-8.33 to 0.68)0.1198
    ≥ 30, < 6061-3.45 (-7.12 to 0.22)0.0719
    ≥ 60, < 9081-1.47 (-4.21 to 1.27)0.2976
    ≥ 90620.11 (-1.87 to 2.08)0.9161